Equity research analysts tracking Artiva Biotherapeutics (NASDAQ: ARTV) maintain a bullish consensus outlook, supported by favorable trial data for AlloNK in refractory autoimmune indications. Consensus 12-month price targets average approximately $27.00 to $35.80 per share, with institutional sentiment buoyed by an FDA RMAT designation and clinical expansion opportunities.